Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Cost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) EPS (Weighted Average and Diluted) (2016 - 2025)

Lifecore Biomedical, Inc. \De\ has reported EPS (Weighted Average and Diluted) over the past 16 years, most recently at -$0.03 for Q2 2025.

  • For Q2 2025, EPS (Weighted Average and Diluted) rose 84.21% year-over-year to -$0.03; the TTM value through May 2025 reached -$1.28, down 574.07%, while the annual FY2025 figure was -$1.27, 484.85% down from the prior year.
  • EPS (Weighted Average and Diluted) for Q2 2025 was -$0.03 at Lifecore Biomedical, Inc. \De\, up from -$0.47 in the prior quarter.
  • Over five years, EPS (Weighted Average and Diluted) peaked at $0.42 in Q1 2024 and troughed at -$1.23 in Q2 2023.
  • A 5-year average of -$0.22 and a median of -$0.24 in 2021 define the central range for EPS (Weighted Average and Diluted).
  • On a YoY basis, EPS (Weighted Average and Diluted) climbed as much as 225.81% in 2023 and fell as far as 925.0% in 2023.
  • Year by year, EPS (Weighted Average and Diluted) stood at $0.25 in 2021, then plummeted by 224.0% to -$0.31 in 2022, then soared by 225.81% to $0.39 in 2023, then tumbled by 164.1% to -$0.25 in 2024, then surged by 88.0% to -$0.03 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for LFCR at -$0.03 in Q2 2025, -$0.47 in Q1 2025, and -$0.25 in Q4 2024.